Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 395 Carcinoma, Non-Small-Cell Lung 203 Breast Neoplasms 167 Ovarian Neoplasms 150 Glioblastoma 136 Neoplasms 112 Carcinoma, Hepatocellular 104 Rectal Neoplasms 98 Colonic Neoplasms 96 Neoplasm Metastasis 94 Brain Neoplasms 86 Lung Neoplasms 77 Fallopian Tube Neoplasms 71 Glioma 62 Carcinoma, Renal Cell 61 Pancreatic Neoplasms 48 Melanoma 40 Gliosarcoma 39 Liver Neoplasms 37 Adenocarcinoma of Lung 36 Uterine Cervical Neoplasms 34 Stomach Neoplasms 34 Recurrence 33 Astrocytoma 28 Endometrial Neoplasms 25 Triple Negative Breast Neoplasms 24 Carcinoma, Ovarian Epithelial 23 Esophageal Neoplasms 21 Kidney Neoplasms 19 Colorectal Cancer Metastatic 18

Interventions

nimotuzumab 1 atezolizumab 1 Tirapazamine 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡